Evidence map›Paper›PMID 30553437›Full record

ArticleThe American journal of pathology2019

Novel mTORC1 Mechanism Suggests Therapeutic Targets for COMPopathies.

Karen L Posey, Francoise Coustry, Alka C Veerisetty, Mohammad G Hossain, Michael J Gambello, Jacqueline T Hecht

Open access · bronzeAbstract read
In one paragraph

Article in The American journal of pathology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
0.6field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 18 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Karen L PoseyDepartment of Pediatrics, McGovern Medical School, University of Texas Health Science Center, Houston, Texas. Electronic address: karen.posey@uth.tmc.edu.
Francoise CoustryDepartment of Pediatrics, McGovern Medical School, University of Texas Health Science Center, Houston, Texas.
Alka C VeerisettyDepartment of Pediatrics, McGovern Medical School, University of Texas Health Science Center, Houston, Texas.
Mohammad G HossainDepartment of Pediatrics, McGovern Medical School, University of Texas Health Science Center, Houston, Texas.
Michael J GambelloHuman Genetics and Pediatrics, Emory University School of Medicine, Atlanta, Georgia.
Jacqueline T HechtDepartment of Pediatrics, McGovern Medical School, University of Texas Health Science Center, Houston, Texas; School of Dentistry, University of Texas Health Science Center, Houston, Texas.
The University of Texas Health Science Center at Houston · USEmory University · US

Funding

Consequences of Mutant COMP Expression and Therapeutic Approaches in Transgenic MiceR01AR057117 · NIAMS · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI HECHT, JACQUELINE T, POSEY, KAREN LASHEA · 2010 to 2020
$4.2M
NIAMS NIH HHS R01 AR057117
6 · The paper itself

Abstract

Cartilage oligomeric matrix protein (COMP) is a large, multifunctional extracellular protein that, when mutated, is retained in the rough endoplasmic reticulum (ER). This retention elicits ER stress, inflammation, and oxidative stress, resulting in dysfunction and death of growth plate chondrocytes. While identifying the cellular pathologic mechanisms underlying the murine mutant (MT)-COMP model of pseudoachondroplasia, increased midline-1 (MID1) expression and mammalian target of rapamycin complex 1 (mTORC1) signaling was found. This novel role for MID1/mTORC1 signaling was investigated since treatments shown to repress the pathology also reduced Mid1/mTORC1. Although ER stress-inducing drugs or tumor necrosis factor α (TNFα) in rat chondrosarcoma cells increased Mid1, oxidative stress did not, establishing that ER stress- or TNFα-driven inflammation alone is sufficient to elevate MID1 expression. Since MID1 ubiquitinates protein phosphatase 2A (PP2A), a negative regulator of mTORC1, PP2A was evaluated in MT-COMP growth plate chondrocytes. PP2A was decreased, indicating de-repression of mTORC1 signaling. Rapamycin treatment in MT-COMP mice reduced mTORC1 signaling and intracellular retention of COMP, and increased proliferation, but did not change inflammatory markers IL-16 and eosinophil peroxidase. Lastly, mRNA from tuberous sclerosis-1/2-null mice brain tissue exhibiting ER stress had increased Mid1 expression, confirming the relationship between ER stress and MID1/mTORC1 signaling. These findings suggest a mechanistic link between ER stress and MID1/mTORC1 signaling that has implications extending to other conditions involving ER stress.

Indexed as

AchondroplasiaCartilage Oligomeric Matrix ProteinDrug Delivery SystemsMechanistic Target of Rapamycin Complex 1AnimalsBiomarkersCell Line, TumorChondrocytesDisease Models, AnimalEndoplasmic Reticulum, RoughEndoplasmic Reticulum StressEosinophil PeroxidaseHumansInflammation MediatorsInterleukin-16MiceBiomarkersCartilage Oligomeric Matrix ProteinComp protein, mouseEosinophil PeroxidaseInflammation MediatorsInterleukin-16Mechanistic Target of Rapamycin Complex 1Mid1 protein, mouseProtein Phosphatase 2ProteinsSirolimusTsc1 protein, mouseTsc2 protein, mouseTuberous Sclerosis Complex 1 ProteinTuberous Sclerosis Complex 2 ProteinTumor Necrosis Factor-alphaUbiquitin-Protein Ligases

Identifiers

PMID30553437
PMCPMC6412713
OpenAlexW2904189794

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.